Hong Kong Pharma Stock News

Semiconductor Manufacturing International (SEHK:981) is back in focus after management issued first quarter 2026 guidance calling for flat sequential revenue and a projected gross margin range of 18% to 20%. See our latest analysis for Semiconductor Manufacturing International. The new first quarter 2026 guidance comes at a time when Semiconductor Manufacturing International’s share price has pulled back in the short term, with a 30 day share price return of 7.54% and a year to date share...

BYD (SEHK:1211) is reported to be in the final bidding round for a Nissan–Mercedes-Benz manufacturing plant in Mexico, which could give it established production capacity in North America and Latin America. The potential acquisition comes as BYD expands international sales, with particular traction reported in European and ASEAN auto markets. These developments highlight BYD's push to build out overseas production and distribution options beyond its existing Chinese manufacturing base. BYD...

SmarTone Telecommunications Holdings (SEHK:315) has put out its H1 2026 scorecard with revenue of HK$3,561.3 million and net income of HK$278.3 million, translating to basic EPS of HK$0.25, while trailing twelve month EPS sits at HK$0.45 on revenue of HK$6,323.2 million. The company has seen revenue move from HK$2,761.9 million in H2 2025 to HK$3,561.3 million in H1 2026, with basic EPS shifting from HK$0.20 to HK$0.25 over the same stretch. This gives a clearer read on how the top and bottom...

Chia Tai Enterprises International (SEHK:3839) has just wrapped up FY 2025 with Q4 revenue of US$105.4 million and net income of US$8.5 million. Trailing 12 month figures show revenue of US$535.9 million and net income of US$32.1 million, alongside a basic EPS of US$0.13. Over the last year, revenue has moved from US$307.7 million on a trailing basis in Q4 FY 2024 to US$535.9 million in Q4 FY 2025, with net income rising from US$11.2 million to US$32.1 million, and EPS lifting from US$0.04 to...

FSE Lifestyle Services (SEHK:331) has reported its H1 2026 numbers with trailing 12 month revenue of HK$7.8b and basic EPS of HK$0.93, while the latest half year data points to revenue of HK$4,069.9m and basic EPS of HK$0.46. The company has seen revenue move from HK$4,333.4m in H2 2024 to HK$4,090.0m in H1 2025 and HK$4,069.9m in H2 2025, with basic EPS over those periods at HK$0.54, HK$0.53 and HK$0.46 respectively. With net income of HK$419.1m over the last 12 months and net profit margin...

JBB Builders International (SEHK:1903) has released its H1 2026 scorecard, reporting trailing 12-month revenue of MYR392.857 million and a small net loss of MYR0.133 million, which translates to basic EPS of a MYR0.000258 loss. The company’s reported half-year revenue has moved between MYR203.025 million in H2 2024 and MYR223.827 million in H1 2025. Over the same periods, basic EPS shifted from MYR0.012022 in H2 2024 to MYR0.003142 in H1 2025 and then to a MYR0.00048 loss in H2 2025,...

During the recent Spring Festival period, COSCO SHIPPING Energy Transportation benefited from a sharp upswing in Very Large Crude Carrier freight rates, which climbed to their highest levels in nearly a decade amid heightened geopolitical tensions and disrupted shipping lanes. The spike in VLCC rates reflects a surge in geopolitical risk premiums and aggressive fixture activity by major charterers, underscoring how external conflict risks can quickly reshape demand and pricing power in the...

JPMorgan’s upgraded outlook for Hong Kong home prices, with forecasts raised to a range of 10% to 15% for this year, has put Henderson Land Development (SEHK:12) back in focus as investors reassess Hong Kong property exposure. See our latest analysis for Henderson Land Development. That optimism is showing up in the trading data, with Henderson Land’s share price at HK$35.32 and recent momentum reflected in a 16.95% 1 month share price return and 21.96% year to date share price return. Its...

Why the CFO change at China Resources Beverage (Holdings) matters now China Resources Beverage (Holdings) (SEHK:2460) has announced a same day handover in its finance leadership, with long serving group executive Ms. HUANG Hu stepping in as chief financial officer after Ms. WU Xia’s resignation. For investors watching a ready to drink beverage business with HK$12,110.817 million in revenue and HK$1,313.688 million in net income, this CFO transition raises questions about capital allocation,...

InSilico Medicine Cayman TopCo (SEHK:3696), an AI focused biotech group, has drawn fresh attention after a recent month of positive share performance, in contrast with weaker daily and past week returns that may interest short term traders. See our latest analysis for InSilico Medicine Cayman TopCo. That recent 4.71% 30 day share price return, despite a 1 day decline of 4.03% and a 7 day share price return of negative 14.76%, sits against a much stronger 74.43% year to date share price return...

Prada’s new bond deal and what it might mean for shareholders Prada (SEHK:1913) has completed a €300 million senior unsecured bond offering, with notes due 2036 priced at 100%. This move may interest equity investors watching the group’s funding mix and liquidity. See our latest analysis for Prada. Prada’s latest bond issue lands after a mixed run for shareholders, with a 7.75% 90 day share price return decline and a 32.13% 1 year total shareholder return decline, despite a 3.90% 7 day share...

CEO transition puts China Mobile (SEHK:941) in focus China Mobile (SEHK:941) is back on investors’ radar after the Board announced that Chief Executive Officer and Executive Director Mr. He Biao resigned due to a work reassignment, effective 12 February 2026. The company confirmed Mr. He’s departure involves no disagreement with the Board. However, leadership changes of this level often prompt investors to revisit expectations for management continuity, capital allocation, and long term...

Profit warning centers investor attention on Skyworth Group Skyworth Group (SEHK:751) has issued new earnings guidance for 2025, flagging an expected 30% drop in annual profit versus 2024. This immediately puts the focus on how its different business segments are holding up. See our latest analysis for Skyworth Group. Despite the profit warning, Skyworth Group’s share price has moved sharply higher in recent months, with an 87.76% 90 day share price return and a very large 1 year total...

Wondering whether Meituan at HK$81.40 is starting to look priced for pessimism or opportunity? This article walks you through what the current market price might be implying about the business. The stock has seen a 0.8% decline over the last 7 days, a 16.6% decline over 30 days, a 22.2% decline year to date, and a 48.7% decline over 1 year, with a 40.2% decline over 3 years and a 77.5% decline over 5 years. These moves have kept Meituan firmly in focus for investors looking at large Chinese...

Guoco Group (SEHK:53) has just posted its H1 2026 scorecard, with the latest half-year context framed by H2 2025 revenue of about US$1.5b, basic EPS of US$0.87 and net income of US$283.1m. Over recent halves the group has reported revenue of US$1.3b in H2 2024, US$1.6b in H1 2025 and then US$1.5b in H2 2025. Over the same periods, basic EPS moved from US$0.84 to US$0.71 and then to US$0.87. This sets up a story where improving net margin and that HK$1.9b one off gain leave overall...

Easy Smart Group Holdings (SEHK:2442) has posted its H1 2026 scorecard with trailing 12 month revenue of HK$270.1 million and a basic EPS loss of HK$0.0191, keeping the focus squarely on whether margins can stop bleeding. The company has seen revenue move from HK$359.2 million with EPS of HK$0.0328 in H1 2025 to HK$314.5 million with an EPS loss of HK$0.0012 in H2 2025 and then to HK$270.1 million with a wider EPS loss of HK$0.0191 on a trailing 12 month basis, so investors are likely to read...

Why the latest irpagratinib trial step matters for Abbisko Cayman (SEHK:2256) Abbisko Cayman (SEHK:2256) has moved its FGFR4 inhibitor irpagratinib into a global Phase I study in the United States. This milestone builds on earlier regulatory designations and clinical data disclosures. See our latest analysis for Abbisko Cayman. Despite the irpagratinib milestones, Abbisko Cayman’s share price has eased recently, with a 30 day share price return of a 7.28% decline and a 90 day share price...

HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater China. See our latest analysis for HBM Holdings. The Solstice agreement arrives as momentum in HBM Holdings' shares has picked up again, with a 1 day share price return of 4.41% and 7 day share price return of 8.12%, while the 1 year total shareholder return of 123.82% and 3 year total shareholder...

Hua Hong Semiconductor (SEHK:1347) is in focus after reporting fourth quarter 2025 results that moved back to net profitability and issuing first quarter 2026 revenue guidance that gives investors clearer near term expectations. See our latest analysis for Hua Hong Semiconductor. Those results sit against a mixed recent trading pattern, with a 4.51% 1 day share price return and a 37.91% 90 day share price return. The 1 year total shareholder return of 137.39% highlights how strongly sentiment...

CARsgen Therapeutics Holdings (SEHK:2171) has entered new cooperation agreements to build a commercial CAR T-cell manufacturing base in Shanghai’s Jinshan District, supporting its existing therapies, late-stage candidates and future allogeneic products. See our latest analysis for CARsgen Therapeutics Holdings. The cooperation news lands as CARsgen’s share price sits at HK$16.14, with a 1-day share price return of 3.33% and 7-day share price return of 7.10%. The 1-year total shareholder...

InnoCare Pharma (SEHK:9969) has drawn fresh investor attention after dosing the first patient in a Phase II/III trial of TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across multiple late stage dermatology programs. See our latest analysis for InnoCare Pharma. The new dermatology trial news comes after a mixed price patch, with a 7.71% 1 month share price return and a 1 year total shareholder return of 63.92%, even though the 90 day share price return shows...

CEO retirement and board changes put ASMPT in focus ASMPT (SEHK:522) has drawn investor attention after announcing that long serving Group CEO Robin Gerard Ng Cher Tat will retire and not seek re election as director, with Executive Director Guenter Walter Lauber also set to depart after the upcoming AGM. See our latest analysis for ASMPT. The leadership changes come as ASMPT’s share price has moved to HK$110.3, with a 5.15% 1 day and 50.48% 90 day share price return, while the 1 year total...

Why Lenovo Group Stock Is On Investors’ Radar Today Lenovo Group (SEHK:992) has drawn investor attention after a period where the share price has moved higher over the past month but remains lower over the past year. With the stock recently closing at HK$9.37 and multi year returns still positive, many holders are reassessing how its current valuation lines up with the company’s earnings profile and growth in both revenue and net income. See our latest analysis for Lenovo Group. Recent moves...

China Medical System Holdings (SEHK:867) has drawn fresh attention after securing exclusive mainland China distribution rights for Lidoderm lidocaine cataplasms and forming an AI-focused drug discovery partnership with Insilico Medicine across multiple R&D programs. See our latest analysis for China Medical System Holdings. The stock’s recent momentum has been firm, with a 12.45% 1 month share price return and 17.77% year to date share price return. The 1 year total shareholder return of...